β-Glucan In Treatment Of Low-density Lipoprotein (ldl) Cholesterol

Preview this chapter:

β-Glucan In Treatment Of Low-density Lipoprotein (ldl) Cholesterol, Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815039238/chapter-6-1.gif

<div&gt;Hypercholesterolemia is one of the most important risk elements of&lt;/div&gt;<div&gt;cardiovascular disease causing metabolic syndrome, diabetes, hypertension. Although&lt;/div&gt;<div&gt;there is a development in this subject, the studies for finding new ways of preventing&lt;/div&gt;<div&gt;and healing dyslipidemia are continuing, and current treatments for cardiovascular&lt;/div&gt;<div&gt;diseases are stimulating different side effects. There are two kinds of β-glucans,</div&gt;<div&gt;insoluble and soluble. These supplements directly interact with biliary salts and lipids&lt;/div&gt;<div&gt;and in the bowel and decrease the level of cholesterol [1]. The patients having&lt;/div&gt;<div&gt;dyslipidemia can be healed by using the therapeutic effect of β-glucans as they do not&lt;/div&gt;<div&gt;create any significant side effects. In this review, the healing effect of β-glucans on&lt;/div&gt;<div&gt;decreasing cholesterol levels in humans. </div&gt;